Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Daiichi Sankyo

< Previous 1 2 3 Next >
Daiichi Sankyo and Merck Enter into Global Development and Commercialization Agreement for MK-6070
From Daiichi Sankyo
Via Business Wire
Tickers MRK
IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer
From Daiichi Sankyo
Via Business Wire
Tickers MRK
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer
From Daiichi Sankyo
Via Business Wire
Tickers MRK
Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
From Daiichi Sankyo
Via Business Wire
Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO
From Daiichi Sankyo
Via Business Wire
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
From Daiichi Sankyo
Via Business Wire
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
From Daiichi Sankyo
Via Business Wire
Tickers AZN
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
From Daiichi Sankyo
Via Business Wire
Tickers MRK
ENHERTU® Granted Priority Review in the U.S. for Patients with Metastatic HER2 Positive Solid Tumors
From Daiichi Sankyo
Via Business Wire
Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
From Daiichi Sankyo
Via Business Wire
Tickers MRK
Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes
From Daiichi Sankyo
Via Business Wire
Daiichi Sankyo Demonstrates Breadth and Depth of Oncology Portfolio Across Multiple Cancers with New Data at ESMO Asia, SABCS and ASH
From Daiichi Sankyo
Via Business Wire
ENHERTU® Demonstrated Clinically Meaningful Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial
From Daiichi Sankyo
Via Business Wire
Datopotamab Deruxtecan Improved Progression-Free Survival Versus Chemotherapy in Patients with Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
From Daiichi Sankyo
Via Business Wire
Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
From Daiichi Sankyo
Via Business Wire
Datopotamab Deruxtecan Plus Durvalumab Demonstrated Robust and Durable Tumor Responses in First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer in BEGONIA Phase 1b/2 Trial
From Daiichi Sankyo
Via Business Wire
Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs
From Daiichi Sankyo
Via Business Wire
Tickers MRK
Daiichi Sankyo Showcases Progress in Developing New Standards of Care for Patients with Industry-Leading DXd ADC Portfolio Across Multiple Cancers at ESMO
From Daiichi Sankyo
Via Business Wire
Datopotamab Deruxtecan Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival Benefit in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
From Daiichi Sankyo
Via Business Wire
ENHERTU® Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2 Mutant Advanced Lung Cancer in DESTINY-Lung02 Phase 2 Trial
From Daiichi Sankyo
Via Business Wire
Datopotamab Deruxtecan Plus Durvalumab Showed Promising Clinical Activity in the First-Line Advanced Non-Small Cell Lung Cancer Setting in TROPION-Lung04 Phase 1b Trial
From Daiichi Sankyo
Via Business Wire
Ifinatamab Deruxtecan Continues to Demonstrate Durable Responses in Patients with Advanced Small Cell Lung Cancer in Early Trial
From Daiichi Sankyo
Via Business Wire
Patritumab Deruxtecan Demonstrated Clinically Meaningful and Durable Responses in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer in HERTHENA-Lung01 Phase 2 Trial
From Daiichi Sankyo
Via Business Wire
DS-3939 Enters Clinical Development in Patients Across Several Types of Advanced Solid Cancers
From Daiichi Sankyo
Via Business Wire
ENHERTU® Granted Two Breakthrough Therapy Designations in U.S. for Patients Across Multiple HER2 Expressing Cancers
From Daiichi Sankyo
Via Business Wire
Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients with Lung Cancer with Data Across DXd ADC Portfolio at WCLC
From Daiichi Sankyo
Via Business Wire
VANFLYTA® Now Available in U.S. for Patients with Newly Diagnosed FLT3-ITD Positive AML
From Daiichi Sankyo
Via Business Wire
ENHERTU® Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial
From Daiichi Sankyo
Via Business Wire
VANFLYTA® First FLT3 Inhibitor Approved in the U.S. Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML
From Daiichi Sankyo
Via Business Wire
Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients with Advanced Non Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
From Daiichi Sankyo
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.